Gender and Mortality after Radical Cystectomy: Competing Risk Analysis by Heberling, Ulrike et al.
 
 
 
 
 
Dieses Dokument ist eine Zweitveröffentlichung (Verlagsversion) / 
This is a self-archiving document (published version):  
 
 
 
 
 
 
 
 
 
 
Diese Version ist verfügbar / This version is available on:  
https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-706429 
 
 
 
 
 
„Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFGgeförderten) Allianz- bzw. 
Nationallizenz frei zugänglich.“ 
 
This publication is openly accessible with the permission of the copyright owner. The permission is 
granted within a nationwide license, supported by the German Research Foundation (abbr. in German 
DFG). 
www.nationallizenzen.de/ 
 
Ulrike Heberling, Rainer Koch, Matthias Hübler, Gustavo B. Baretton, Oliver W. 
Hakenberg, Manfred P. Wirth, Michael Froehner  
Gender and Mortality after Radical Cystectomy: Competing Risk 
Analysis 
 
Erstveröffentlichung in / First published in: 
Urologia Internationalis. 2018, 101 (3), S. 293 – 299 [Zugriff am: 19.05.2020]. Karger. ISSN 
1423-0399.  
DOI: https://doi.org/10.1159/000487445  
  
Original Paper
Urol Int 2018;101:293–299
Gender and Mortality after Radical 
Cystectomy: Competing Risk Analysis
Ulrike Heberling a    Rainer Koch b    Matthias Hübler c    Gustavo B. Baretton d    
Oliver W. Hakenberg e    Manfred P. Wirth a    Michael Froehner a    
a
 Departments of Urology, Dresden, Germany; b Departments of Medical Statistics and Biometry, Dresden, Germany; 
c
 Departments of Anesthesiology, Dresden, Germany; d Departments of Pathology, University Hospital Carl 
Gustav Carus, Technische Universität Dresden, Dresden, Germany; e Department of Urology, University of Rostock, 
Rostock, Germany
Received: November 30, 2017
Accepted after revision: February 2, 2018
Published online: August 31, 2018
Internationalis
Urologia
Michael Froehner, MD
Department of Urology, University Hospital “Carl Gustav Carus”
Technische Universität Dresden, Fetscherstrasse 74
DE–01307 Dresden (Germany)
E-Mail Michael.Froehner @ uniklinikum-dresden.de
© 2018 S. Karger AG, Basel
E-Mail karger@karger.com
www.karger.com/uin
DOI: 10.1159/000487445
Keywords
Urologic neoplasms · Gender · Comorbidity · Bladder · 
Cystectomy · Competing risk analysis · Proportional hazards 
model
Abstract
Background: Data on the impact of gender on mortality af-
ter radical cystectomy is conflicting. We investigated a large 
single center sample with long-term follow-up in order to 
determine the relationship between gender and outcome. 
Patients and Methods: A total of 1,184 consecutive patients 
who underwent radical cystectomy for high risk superficial 
or muscle-invasive urothelial or undifferentiated bladder 
cancer between 1993 and 2015 were stratified by gender. 
Demographic data was compared using Mann-Whitney U 
test, chi-square test, or Fisher exact test. Cox proportional 
hazard models were used for the analysis of competing risks 
and logit models were used for the prediction of the receipt 
of adjuvant cisplatin-based chemotherapy. Results: Female 
patients were older, healthier, less frequently current smok-
ers and had more extravesical tumors. In the multivariate 
analyses, female gender was an independent predictor of 
(lower) non-bladder cancer (competing) mortality (hazards 
ratio [HR] 0.68, 95% CI 0.49–0.95, p = 0.0248) but no predictor 
of bladder cancer-specific mortality (HR in the full model 
1.20, 95% CI 0.94–1.54, p = 0.15). Gender was no predictor of 
the receipt of adjuvant cisplatin-based chemotherapy. Con-
clusions: Female gender was associated with an increased 
risk of extravesical disease but was no independent predic-
tor of bladder cancer-specific mortality. Anatomical differ-
ences might be a plausible explanation for these observa-
tions. © 2018 S. Karger AG, Basel
Introduction
Data on the impact of gender on mortality after radical 
cystectomy is conflicting. Female patients have been 
found to harbor a higher mortality risk after radical cys-
tectomy [1–3]. The reasons for this phenomenon are dis-
cussed controversially [1]. Other authors, however, did 
not observe gender-related outcome differences [4–6]. 
We investigated a large single center sample with long-
term follow-up in order to identify gender-related differ-
ences in prognostic parameters and in the mortality risk 
from bladder cancer and from competing causes.
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Patients and Methods
Study Sample
The study sample consisted of 1,184 patients who consecutive-
ly underwent radical cystectomy for high risk superficial or mus-
cle-invasive urothelial or undifferentiated bladder cancer at our 
institution between 1993 and 2015. Institutional review board ap-
proval was obtained. The patients were stratified into males and 
females.
Data Collection
Tumor-related and patient-related data were obtained from 
patient charts. Demographic data is shown in Table 1. Follow-up 
information and data on the receipt of adjuvant cisplatin-based 
chemotherapy were obtained from patient charts, office urolo-
gists, general practitioners, the local tumor registry, local authori-
ties, health insurances, the patients themselves, or their relatives. 
Deaths from all causes were considered events concerning overall 
mortality. Deaths from uncontrolled bladder cancer were consid-
Table 1. Demographic data of the study sample. Tumor stages are given as the cystectomy and lymph node dissection specimen tumor 
stages according to the 2017 TNM classification [7]. Patients initially classified as pT3a according to the 1992 TNM classification (inva-
sion of deep bladder detrusor muscle) were reclassified as pT2 according the current classification
Parameter Overall, 
n (%)
Males, 
n (%)
Females, 
n (%)
p value*
Sample size 1,184 (100) 929 (78.5) 255 (21.5) –
Follow-up, censored patients, years, mean 7.34 7.32 7.43 0.28
BMI, kg/m2, mean 27.0 27.0 26.9 0.23
Age, years, mean 68.7 68.0 71.1 <0.0001
Mean number of removed lymph nodes** 17.4 17.6 16.5 0.11
Extravesical disease (pT3–4 [7]) 500 (42.2) 366 (39.4) 134 (52.5) 0.0002
Positive lymph nodes (pN1–3 [7]) 308 (26.0) 239 (26.3) 69 (28.0) 0.59
Extravesical disease and positive lymph nodes (pT3–4 and pN1–3 [7]) 232 (19.6) 173 (18.6) 59 (23.1) 0.11
Extravesical disease or positive lymph nodes (pT3–4 or pN1–3 [7]) 576 (48.6) 432 (46.5) 144 (56.5) 0.0048
ASA classes 3–4 493 (41.6) 383 (41.2) 110 (43.1) 0.58
CCS classes 2–4 131 (11.1) 107 (11.5) 24 (9.4) 0.34
NYHA classes 2–4 211 (17.8) 162 (17.4) 49 (19.2) 0.51
Charlson score 2 or higher 449 (37.9) 365 (39.3) 84 (32.9) 0.06
Charlson score 2 or higher and ASA classes 3–4 305 (25.8) 247 (26.6) 58 (22.7) 0.21
Diabetes mellitus 288 (24.3) 234 (25.2) 54 (21.2) 0.19
Diabetes mellitus with end organ damage 149 (12.6) 129 (13.9) 20 (7.8) 0.0100
Chronic lung disease 218 (18.4) 192 (20.7) 26 (10.2) 0.0001
History of myocardial infarction 86 (7.3) 73 (7.9) 13 (5.1) 0.13
Cerebrovascular disease 65 (5.5) 56 (6.0) 9 (3.5) 0.12
Peripheral vascular disease 129 (11.0) 111 (11.9) 18 (7.1) 0.0264
Any neoadjuvant chemotherapy 55 (4.6) 47 (5.1) 8 (3.1) 0.20
Adjuvant cisplatin-based chemotherapy 258 (21.8) 202 (21.8) 56 (22.0) 0.97
Current smokers 327 (27.6) 288 (31.0) 39 (15.3) <0.0001
Continent urinary diversion 390 (32.9) 363 (39.1) 27 (10.6) <0.0001
90-Day mortality 50 (4.2) 35 (3.8) 15 (5.9) 0.14
Deaths from any cause 650 (54.9) 508 (54.7) 142 (55.7) 0.78
Deaths from non-cancer causes 205 (17.3) 164 (17.7) 41 (16.1) 0.78
Deaths from bladder cancer 372 (31.4) 278 (29.9) 94 (36.9) 0.0345
Deaths from second cancers 66 (5.6) 60 (6.5)*** 6 (2.4)**** 0.0114
Deaths from unknown causes 7 (0.6) 6 (0.6) 1 (0.4) 1.00
* p values are given for Mann-Whitney U test for quantitative variables, chi-square test or Fisher exact test for binary variables.
** Patients without a known number of removed lymph nodes were excluded for the calculation of the mean value.
*** Most common types: lung, gastric or duodenal, lymphoma/leukemia/plasmocytoma, hepatocellular, cholangiocellular, or gall 
bladder.
**** Lung (n = 2), pancreas (n = 2), leukemia, tongue.
CCS, classification of angina pectoris of the Canadian Cardiovascular Society; NYHA, classification of cardiac insufficiency of the 
New York Heart Association; ASA, American Society Association physical status classification; TNM, tumor node metastasis; BMI, body 
mass index. 
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ered events concerning bladder cancer-specific mortality. Deaths 
from other causes or from unknown causes were considered 
events concerning (competing) non-bladder cancer mortality. 
Further analogous analyses were performed with deaths from un-
controlled second cancers and deaths from non-cancer causes as 
endpoints.
Statistical Analysis
Demographic data were compared using Mann-Whitney U 
test, chi-square test, or Fisher exact test. Kaplan-Meier curves were 
used for the analysis of overall mortality whereas competing risk 
analysis was used for the analysis of individual causes of death. 
Univariate comparisons of mortality curves were done with the 
log-rank test (overall mortality) and the Pepe Mori test (competing 
risk analyses), respectively. Cox proportional hazard models were 
used for the analysis of competing risks and logit models were used 
for the prediction of the receipt of adjuvant cisplatin-based che-
motherapy. The analyses were performed with the Statistical Anal-
ysis Systems version 9.4 statistical package (SAS Institute, Cary, 
NC, USA).
Results
In the current study, female patients were older, 
healthier, less frequently current smokers and had more 
frequently extravesical tumors, compared with their male 
counterparts (Table 1). In the univariate analysis, overall 
mortality did not differ between females and males (10-
year rates 61.0 vs. 59.1%, p = 0.35; Fig. 1). Female patients 
had, however, a higher bladder cancer-specific mortality 
(10-year rates 41.5 vs. 34.1%, p = 0.0067; Fig. 2). Where-
as there was no detectable relationship between gender 
and non-cancer mortality, female gender was associated 
with a trend toward lower second cancer mortality (10-
year rates 2.9 vs. 7.0%, p = 0.17; Fig. 2). After stratification 
by the local tumor extent (bladder confined versus extra-
vesical), bladder cancer-specific mortality was virtually 
identical in females and males with bladder confined tu-
mors, whereas there was still some trend toward in-
creased bladder cancer-specific mortality in females in 
patients with extravesical or lymph node-positive disease 
(Fig. 3).
In the multivariable analyses, female gender was an 
independent predictor of (lower) competing mortality 
(hazards ratio [HR] 0.68, 95% CI 0.49–0.95, p = 0.0248) 
but no predictor of bladder cancer-specific mortality (HR 
in the full model 1.20, 95% CI 0.94–1.54, p = 0.15; Table 
2). Concerning second cancer mortality, female gender 
narrowly missed the significance level in the multivari-
able analysis as a predictor of (lower) mortality (HR 0.43, 
95% CI 0.18–1.04, p = 0.06; Table 2). Nevertheless, lower 
competing mortality in females was largely contributable 
to a lower incidence of fatal second cancers (Table 1; 
Fig. 2). Multivariable logit models predicting the proba-
bility of receipt of adjuvant cisplatin-based chemotherapy 
are shown in Table 3. The impact of gender was negligible 
compared with that of tumor-related variables, age and 
comorbidity (Table 3).
Discussion
In this study, female gender was associated with an in-
creased risk of extravesical disease. The resulting in-
creased bladder cancer-specific mortality risk in the uni-
variate analysis disappeared after controlling for stage 
and other possible confounders. 
In contrast to a comparable multicenter study [3], 
there was a more pronounced overweight of locally ad-
vanced tumor stages (extravesical disease: 39.4% in males 
vs. 52.5% in females in the current study, Table 1 vs. pT3–
4: 43.0% in males and 46.5% in females [3]). On the other 
hand, in this study, female gender was no independent 
predictor of bladder cancer-specific mortality. In the cit-
ed multicenter study, with a HR of 1.17 in the multivari-
able analysis, the impact of gender was relatively small 
compared with that of tumor stage-related variables [3]. 
It is conceivable that gender-related effects not attribut-
able to the confounders (Table 2) were too small to be-
come demonstrable in our single center study. Patient re-
cruitment in the cited study [3] started in 1971 and adju-
vant chemotherapy was (in contrast to the current study; 
Table 2) not associated with improved survival [3]. A 
Years after radical cystectomy
p = 0.35
Females
Males
20181614121086420
0
0.2
0.4
0.6
0.8
1.0
Fig. 1. Cumulative overall mortality after radical cystectomy strat-
ified by gender. The p value is given for the log-rank test.
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somewhat greater age difference between males and fe-
males (1 year [3] vs. 3.1 years in this study) and a less fa-
vorable stage distribution in females are further demo-
graphic differences between the current and the cited 
study [3]. A similar difference between females and males 
concerning the presence of extravesical disease (T3–4, 
58.7 vs. 47.2% [8]) as in the current study was observed in 
a recent multicenter study from Austria [7], whereas in a 
Canadian multicenter study that observed narrowly iden-
tical mortality rates lower differences (T3–4 in females 61 
vs. 58% in males [6]) were found. In one multicenter 
study, a lower 90-day mortality rate was observed in fe-
males [9], a finding that was not confirmed in our study 
(Table 1).
Years after radical cystectomy
Non-cancer causes, p = 0.98
20181614121086420
0
0.2
0.4
0.6
0.8
1.0
Second cancers, p = 0.17
20181614121086420
0
0.2
0.4
0.6
0.8
1.0
Non-bladder cancer causes overall, p = 0.69
20181614121086420
0
0.2
0.4
0.6
0.8
1.0
Bladder cancer, p = 0.0067
20181614121086420
0
0.2
0.4
0.6
0.8
1.0
Females
Males
Fig. 2. Cumulative mortality from bladder cancer, non-bladder cancer (competing) causes overall, non-cancer causes and second can-
cers, respectively, stratified by gender. p values are given for the Pepe Mori test.
Bladder confined disease, p = 0.90
20181614121086420
0
0.2
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1.0
Years after radical cystectomy
20181614121086420
0
0.2
0.4
0.6
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1.0
Extravesical disease, p = 0.16 Positive lymph nodes, p = 0.35
20181614121086420
0
0.2
0.4
0.6
0.8
1.0
Females
Males
Fig. 3. Bladder cancer-specific mortality analyzed separately in patients with bladder confined primary tumors (<pT3 [7]), extravesical 
primary tumors (pT3–4 [7]), and positive lymph nodes (pN1–3 [7]), respectively, stratified by gender. p values are given for the Pepe 
Mori test.
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Whereas in 2 multicenter studies which started pa-
tient recruitment in 1971 [3] and 1979 [10] higher blad-
der cancer-specific mortality after radical cystectomy 
was observed in females, a multicenter study enrolling 
patients between 1994 and 2008 did not find measurable 
gender-related mortality differences [6]. Several possi-
ble explanations have been discussed for the overweight 
of more advanced tumor stages and for the adverse out-
come in females with bladder cancer [1]. Beside a de-
layed diagnosis in females, hormonal differences and 
Table 2. Optimal multivariable models for the endpoints overall mortality, bladder cancer-specific mortality, non-bladder cancer (com-
peting) mortality overall, non-cancer mortality, and second cancer mortality. Beside the variables identified as independent predictors 
of overall mortality, the following three variables (that were not significantly associated with this endpoint) were included in these mul-
tivariable analyses: gender (female vs. male), smoking status (current smokers vs. none-smokers, former smokers, or unknown smoking 
status), and BMI (as a continuous variable, per unit increase)
Category HR 95% CI p value
Endpoint overall mortality
Age (continuous variable, per year increase) 1.02 1.01–1.03 <0.0001
Charlson score (continuous variable, per unit increase) 1.12 1.07–1.16 <0.0001
ASA classes 3–4 (versus 1–2) 1.54 1.29–1.88 <0.0001
Extravesical disease (pT3–4 [7]; versus bladder confined disease, <pT3 [7]) 2.21 1.85–2.63 <0.0001
Positive lymph nodes (pN1–3 [7]; versus negative lymph nodes or unknown, pN0-x [7]) 2.66 2.17–3.27 <0.0001
Number of removed lymph nodes <17 or unknown (versus 17 or more*) 1.22 1.041.43 0.0126
Any neoadjuvant chemotherapy (versus none) 1.81 1.31–2.50 0.0014
Adjuvant cisplatin-based chemotherapy (versus none or unknown) 0.52 0.42–0.65 <0.0001
Endpoint bladder cancer-specific mortality
Extravesical disease (pT3–4 [7]; versus bladder confined disease, <pT3 [7]) 2.55 2.00–3.24 <0.0001
Positive lymph nodes (pN1–3 [7]; versus negative lymph nodes or unknown, pN0-x [7]) 3.41 2.63–4.42 <0.0001
Any neoadjuvant chemotherapy (versus none) 2.38 1.60–3.53 <0.0001
Adjuvant cisplatin-based chemotherapy (versus none or unknown) 0.71 0.54–0.92 0.0103
Endpoint non-bladder cancer (competing) mortality overall
Age (continuous variable, per year increase): 1.05 1.04–1.07 <0.0001
Charlson score (continuous variable, per unit increase) 1.16 1.09–1.24 <0.0001
ASA classes 3–4 (versus 1–2) 1.64 1.24–2.15 0.0248
Positive lymph nodes (pN1–3 [7]; versus negative lymph nodes or unknown, pN0-x [7]) 0.44 0.31–0.62 <0.0001
Number of removed lymph nodes <17 or unknown (versus 17 or more*) 0.74 0.58–0.94 0.0156
Current smokers (versus none-smoker, former smoker or unknown) 1.60 1.24–2.08 0.0004
Gender female (versus male) 0.68 0.49–0.95 0.0248
Endpoint non-cancer mortality
Age (continuous variable, per year increase) 1.06 1.06–1.08 <0.0001
Charlson score (continuous variable, per unit increase) 1.13 1.06–1.21 <0.0001
ASA classes 3–4 (versus 1–2) 2.02 1.48–2.75 <0.0001
Positive lymph nodes (versus negative lymph nodes or unknown) 0.43 0.29–0.63 <0.0001
Current smokers (versus none-smokers, former smokers or unknown) 1.40 1.02–1.92 0.0393
Endpoint second cancer mortality
BMI (continuous variable, per unit increase) 0.95 0.90–1.00 0.0463
Charlson score (continuous variable, per unit increase) 1.21 1.09–1.35 0.0004
Positive lymph nodes (pN1-3 [7]; versus negative lymph nodes or unknown, pN0-x [7]) 0.48 0.25–0.95 0.0340
Current smokers (versus none-smoker, former smoker or unknown) 1.95 1.19–3.19 0.0082
* Stratified by the median number or removed lymph nodes; In the full model, the HR for the endpoint bladder cancer-specific mortality 
for 17 or more removed lymph nodes was 0.94 (95% CI 0.76–1.16, p = 0.56).
In the full models, the following HRs for female gender were observed: endpoint overall mortality: 0.98 (95% CI 0.81–1.18, p = 0.80); end-
point bladder cancer-specific mortality: 1.20 (95% CI 0.94–1.54, p = 0.15); endpoint non-bladder cancer (competing) mortality overall: 0.69 
(95% CI 0.49–0.96, p = 0.0300); endpoint non-cancer mortality: 0.82 (95% CI 0.58–1.18, p = 0.30); endpoint second cancer mortality: 0.43 (95% 
CI 0.18–1.04, p = 0.06).
ASA, American society association physical status classification; HR, hazard ratio; BMI, body mass index.
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differences in treatment have been blamed [1, 3, 9, 10]. 
Since gender-related outcome differences seemed to di-
minish in more recent times, some authors speculated 
on time-dependent differences in awareness or access to 
treatment in females [9]. In the current study, there was 
a higher incidence of extravesical disease in females 
(52.5 vs. 39.4%) without a relevant difference in the in-
cidence of lymph node metastases (28.0 vs. 26.3%) and 
a virtually identical outcome of males and females with 
bladder confined primary tumor (Fig. 3). These obser-
vations might fit to the hypothesis that anatomical dif-
ferences (a thicker bladder wall in males that needs to 
be crossed by the tumor in order to reach adjacent 
structures and major intrinsic differences in pelvic anat-
omy that may influence tumor spread [11–13]) might 
explain the mortality differences between males and fe-
males after radical cystectomy. Anatomical differences 
might also explain the fact that a higher mortality in 
females with bladder cancer contrasts to a lower mortal-
ity in females seen in a great variety of other cancers 
[14].
The results of this study do not support the hypoth-
esis that female candidates for radical cystectomy should 
undergo more intense treatment and follow-up [2] since 
the stage-adjusted mortality rates did not differ mean-
ingfully (Table 2; Fig.  2). Encouraging more patients 
with extravesical or lymph node-positive disease to un-
dergo adjuvant cisplatin-based chemotherapy irrespec-
tive of gender might be a more promising approach to 
decrease bladder-cancer specific mortality (Table 2). 
The 21.8% rate of administration of adjuvant cisplatin-
based chemotherapy in the current study was narrowly 
identical with the rates observed in multicenter studies 
[3, 6]. This rate contrasts with 48.9% high risk patients 
with either extravesical or lymph node-positive disease 
who could be candidates for such treatment (Table 1). 
In this study, gender was no predictor of the adminis-
tration of adjuvant cisplatin-based chemotherapy (Ta-
ble 3). It is, therefore, unlikely that differences in its use 
contributed meaningfully to gender-related mortality 
differences.
With more patients available for analysis, the current 
study stabilized the results of earlier analyses, that is, the 
association of the number of removed lymph nodes 
(stratified by the median) with overall, competing but not 
with bladder cancer-specific mortality [15], the associa-
tion of adjuvant cisplatin-based chemotherapy with 
overall, disease-specific but not with competing mortal-
ity [16] now reaching the significance level for the latter 
endpoint and the association of current smoking with 
competing but not bladder cancer-specific and overall 
mortality [17] (data shown in Table 2). Since most fatal 
second cancers in this study (Table 1) are known to be 
associated with smoking [18], the differing prevalence of 
smoking among females and males (Table 1) might ex-
plain the trend toward lower mortality from second can-
cers in females in this study.
This study has limitations and strengths. Although the 
sample size is relatively large for a single center study, 
multicenter studies are able to investigate considerably 
Table 3. Full and optimal multivariable logit models predicting the application of adjuvant cisplatin-based chemotherapy. Beside the 
impact of the plausible predictors, that of gender was negligible in these models
Category Full model Optimal model
OR 95% CI p value OR 95% CI p value
Age: (continuous variable, per year increase) 0.93 0.91–0.95 <0.0001 0.93 0.91–0.95 <0.0001
Charlson score: (continuous variable, per unit increase) 0.80 0.70–0.91 0.0006 0.78 0.70–0.89 <0.0001
ASA class: (3–4 vs. 1–2) 0.85 0.55–1.31 0.47
Extravesical disease (pT3–4 [7]): (yes vs. no) 6.20 4.13–9.30 <0.0001 6.03 4.03–9.01 <0.0001
Positive lymph nodes (pN1–3 [7]): (yes vs. no or unknown) 12.83 8.64–19.05 <0.0001 12.38 8.41–18.22 <0.0001
Number of removed lymph nodes: (<17 or unknown vs. 17 or more*) 0.69 0.48–0.99 0.0460 0.69 0.48–0.99 0.0453
Any neoadjuvant chemotherapy: (yes vs. no) 0.89 0.42–1.92 0.77
Adjuvant cisplatin-based chemotherapy: (yes vs. no) Variable not included into this analysis
Gender: (female vs. male) 0.79 0.50–1.23 0.29
Smoking status: (current smokers vs. others**) 0.75 0.49–1.16 0.20
Body mass index: (continuous variable, per unit increase) 0.90 0.95–1.03 0.65
* Stratified by the median number or removed lymph nodes.
** None-smokers, former smokers, or unknown smoking status.
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larger samples in order to identify small effects and to 
perform subgroup analyses. On the other hand, in this 
series, follow-up was substantially longer than in compa-
rable studies [3, 4, 9, 10]. Whereas only crude stratifica-
tions were available to adjust for tumor-related parame-
ters, in contrast to other studies [3, 4, 9, 10] relatively de-
tailed data were available to control for comorbidity and 
the causes of death were classified in detail allowing com-
peting risk analyses for different causes of death. It may, 
however, not be ruled out that unmeasured confounders 
influenced the results. Finally, the fact that treatment and 
patient selection might have changed during the relative-
ly long recruitment period is another possible limitation 
of this study. 
Conclusion
Female gender was associated with an increased risk of 
extravesical disease. The resulting increased bladder can-
cer-specific mortality risk in the univariate analysis disap-
peared after controlling for stage and other possible con-
founders in the multivariable analysis. Anatomical differ-
ences might be a plausible explanation for these 
observations.
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